AveXis, Inc.
(NASDAQ : AVXS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 2.91%69.000.0%$1713.15m
GILDGilead Sciences, Inc. -0.22%73.341.0%$1486.09m
AMGNAmgen, Inc. 0.73%226.431.3%$647.45m
REGNRegeneron Pharmaceuticals, Inc. 1.59%569.912.5%$560.12m
VRTXVertex Pharmaceuticals, Inc. 0.12%284.961.9%$540.88m
NVAXNovavax, Inc. -7.91%46.11102.0%$530.71m
BIIBBiogen, Inc. 0.02%304.531.6%$447.72m
ILMNIllumina, Inc. 1.51%354.703.5%$344.73m
SRNESorrento Therapeutics, Inc. 0.80%5.071.8%$271.93m
SGENSeattle Genetics, Inc. 1.02%155.776.1%$227.64m
ALXNAlexion Pharmaceuticals, Inc. 0.36%101.502.0%$215.96m
CODXCo-Diagnostics, Inc. 2.94%18.550.0%$192.06m
AAgilent Technologies, Inc. 5.24%84.981.6%$187.17m
IMMUImmunomedics, Inc. -0.69%34.4711.0%$184.11m
MGNXMacroGenics, Inc. 0.84%25.376.2%$182.51m

Company Profile

Based in Dallas, Texas, AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.